AU776541B2 - Pegylated interferon alfa-CCR5 antagonist combination HIV therapy - Google Patents

Pegylated interferon alfa-CCR5 antagonist combination HIV therapy Download PDF

Info

Publication number
AU776541B2
AU776541B2 AU46815/00A AU4681500A AU776541B2 AU 776541 B2 AU776541 B2 AU 776541B2 AU 46815/00 A AU46815/00 A AU 46815/00A AU 4681500 A AU4681500 A AU 4681500A AU 776541 B2 AU776541 B2 AU 776541B2
Authority
AU
Australia
Prior art keywords
alkyl
hydrogen
phenyl
group
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU46815/00A
Other languages
English (en)
Other versions
AU4681500A (en
Inventor
Mark A. Laughlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AU4681500A publication Critical patent/AU4681500A/en
Application granted granted Critical
Publication of AU776541B2 publication Critical patent/AU776541B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU46815/00A 1999-05-04 2000-05-01 Pegylated interferon alfa-CCR5 antagonist combination HIV therapy Ceased AU776541B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30489799A 1999-05-04 1999-05-04
US09/304897 1999-05-04
PCT/US2000/011634 WO2000066141A2 (en) 1999-05-04 2000-05-01 Pegylated interferon alfa-ccr5 antagonist combination hiv therapy

Publications (2)

Publication Number Publication Date
AU4681500A AU4681500A (en) 2000-11-17
AU776541B2 true AU776541B2 (en) 2004-09-16

Family

ID=23178462

Family Applications (1)

Application Number Title Priority Date Filing Date
AU46815/00A Ceased AU776541B2 (en) 1999-05-04 2000-05-01 Pegylated interferon alfa-CCR5 antagonist combination HIV therapy

Country Status (21)

Country Link
EP (1) EP1175224B1 (enExample)
JP (1) JP2002543144A (enExample)
CN (1) CN1349408A (enExample)
AR (1) AR023824A1 (enExample)
AT (1) ATE289516T1 (enExample)
AU (1) AU776541B2 (enExample)
BR (1) BR0010593A (enExample)
CA (1) CA2365900A1 (enExample)
DE (1) DE60018273T2 (enExample)
ES (1) ES2238277T3 (enExample)
HK (1) HK1039278B (enExample)
HU (1) HUP0202734A3 (enExample)
MX (1) MXPA01011116A (enExample)
MY (1) MY127670A (enExample)
NO (1) NO328679B1 (enExample)
NZ (1) NZ514519A (enExample)
PE (1) PE20010283A1 (enExample)
PT (1) PT1175224E (enExample)
TW (1) TWI289454B (enExample)
WO (1) WO2000066141A2 (enExample)
ZA (1) ZA200108870B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050065319A1 (en) * 2000-12-19 2005-03-24 Baroudy Bahige M. Combination method for treating viral infections
CA2517888C (en) 2003-03-14 2012-05-01 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
EP2364982A1 (en) 2003-04-18 2011-09-14 ONO Pharmaceutical Co., Ltd. Spiro-piperidine compounds as chemokine receptor antagonists and medicinal use thereof
EP1616862A4 (en) * 2003-04-18 2008-07-16 Ono Pharmaceutical Co HETEROCYCLIC NITROGEN COMPOUND AND USE THEREOF
ES2294589T3 (es) 2004-04-29 2008-04-01 F. Hoffmann-La Roche Ag Variacion de la secuencia nucleosida de ns5a como marcador.
PE20060598A1 (es) 2004-09-13 2006-08-21 Ono Pharmaceutical Co Derivado heterociclo conteniendo nitrogeno como antagonista de quimiocina ccr5
AU2006216731A1 (en) * 2005-02-23 2006-08-31 Schering Corporation Piperidinyl piperazine derivatives useful as inhibitors of chemokine receptors
US20110052612A1 (en) 2005-05-31 2011-03-03 Ono Pharmaceutical Co., Ltd. Spiropiperidine compound and medicinal use thereof
EP2657235A1 (en) 2005-10-28 2013-10-30 Ono Pharmaceutical Co., Ltd. Compound containing basic group and use thereof
US8168783B2 (en) 2005-11-18 2012-05-01 Ono Pharmaceutical Co., Ltd. Chemokine receptor antagonists and use thereof
KR20090008217A (ko) 2006-03-10 2009-01-21 오노 야꾸힝 고교 가부시키가이샤 질소 함유 복소환 유도체 및 이들을 유효 성분으로 하는 약제
WO2007132846A1 (ja) 2006-05-16 2007-11-22 Ono Pharmaceutical Co., Ltd. 保護されていてもよい酸性基を含有する化合物およびその用途
US20090325992A1 (en) 2006-07-31 2009-12-31 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
AU2012338581B2 (en) 2011-11-18 2016-12-08 Nxera Pharma Uk Limited Muscarinic M1 receptor agonists
SG11201605440TA (en) 2014-01-08 2016-08-30 Immunovative Therapies Ltd Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
ES2214551T3 (es) * 1995-11-02 2004-09-16 Schering Corporation Terapia de infusion continua de citocinas a baja dosis.
GB9609932D0 (en) * 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
WO1998025617A1 (en) * 1996-12-13 1998-06-18 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
AR013669A1 (es) * 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos

Also Published As

Publication number Publication date
EP1175224B1 (en) 2005-02-23
JP2002543144A (ja) 2002-12-17
BR0010593A (pt) 2002-02-13
PT1175224E (pt) 2005-07-29
ES2238277T3 (es) 2005-09-01
HUP0202734A2 (hu) 2002-12-28
AR023824A1 (es) 2002-09-04
WO2000066141A3 (en) 2001-02-08
CA2365900A1 (en) 2000-11-09
TWI289454B (en) 2007-11-11
DE60018273D1 (de) 2005-03-31
DE60018273T2 (de) 2005-08-18
NO20015367L (no) 2002-01-03
ZA200108870B (en) 2003-03-26
NO328679B1 (no) 2010-04-26
NZ514519A (en) 2003-07-25
MXPA01011116A (es) 2002-06-04
HK1039278B (en) 2005-06-30
CN1349408A (zh) 2002-05-15
WO2000066141A2 (en) 2000-11-09
HK1039278A1 (en) 2002-04-19
MY127670A (en) 2006-12-29
PE20010283A1 (es) 2001-03-16
AU4681500A (en) 2000-11-17
HUP0202734A3 (en) 2003-11-28
EP1175224A2 (en) 2002-01-30
ATE289516T1 (de) 2005-03-15
NO20015367D0 (no) 2001-11-02

Similar Documents

Publication Publication Date Title
AU776541B2 (en) Pegylated interferon alfa-CCR5 antagonist combination HIV therapy
ZA200307474B (en) CCR5 antagonists useful for treating AIDS.
US6635646B1 (en) Pegylated interferon alfa-CCR5 antagonist combination HIV therapy
US20020004584A1 (en) HIV immune adjuvant therapy
US20070123538A1 (en) Compositions comprising a combination of CCR5 and CXCR4 antagonists
US20050065319A1 (en) Combination method for treating viral infections
EP1034790A2 (en) HIV therapy
US20020182179A1 (en) HIV Therapy
HK1027286A (en) Hiv therapy
AU2002245148A1 (en) CCR5 antagonist and DP-178 polypeptide for treating viral infections
Pockros Current status of immunomodulatory therapies in HCV infection
MX2008007042A (en) Compositions comprising a combination of ccr5 and cxcr4 antagonists